Anavex Life Sciences Corp (OTCBB: AVXL) will move to human clinical trials for its Alzheimer’s drug in early 2009 after preclinical studies on mice prove promising.
“The completion of preclinical studies is a key milestone for our company,” said Anavex President Harvey Lalach. “Our novel approach is based on Anavex’s expertise and leadership in the field of sigma receptors and our highly productive drug discovery platform.
Anavex calls their ANAVEX 2-73 drug a “novel sigma-1 receptor.” During testing, so far, it demonstrated “significant neuroprotective, anti-amnesic and anti-convulsive properties” at low doses. “It has been shown to provide protection from oxidative stress, which damages and destroys neurons and is believed to be a primary cause of Alzheimer’s disease,” a company news release states.
Preclinical studies on ANAVEX 1-41, another lead compound targeting Alzheimer’s disease and depression, are scheduled for completion by the end of the year.
Let us hear your thoughts below: